The Atrioventricular Coupling in Heart Failure: Pathophysiological and Therapeutic Aspects
Vito Di Terlizzi1, Roberta Barone1, Nicola Di Nunno1
1Cardiology Unit, University Policlinic Hospital Riuniti, 71122 Foggia, Italy.
Reviews in Cardiovascular Medicine
|July 30, 2024
Summary
This review highlights the importance of atrioventricular coupling in heart failure. Understanding this interaction is key to diagnosing and treating various heart conditions effectively.
Area of Science:
- Cardiology
- Cardiac Physiology
Background:
- Historically, heart failure research focused on individual heart chambers.
- Emerging research emphasizes the critical role of atrioventricular (AV) coupling in cardiac function.
Purpose of the Study:
- To review the principles of AV function and coupling in the left heart.
- To explore the impact of disrupted AV coupling on cardiovascular diseases.
- To discuss diagnostic and therapeutic strategies for AV coupling dysfunction.
Main Methods:
- Literature review of current research on AV coupling.
- Analysis of echocardiographic techniques for assessing AV function.
- Overview of recent pharmacological and device-based therapies.
Main Results:
- Altered AV coupling significantly impacts global heart performance and contributes to heart failure.
- Echocardiography provides valuable insights into chamber function and AV synchrony.
- Novel therapeutic approaches are emerging for managing AV coupling abnormalities.
Conclusions:
- Atrioventricular coupling is a crucial determinant of cardiac health and a key factor in heart failure.
- Accurate assessment of AV coupling is essential for effective clinical management.
- Advances in pharmacotherapy and device therapy offer new hope for patients with AV coupling disorders.
More Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:29Pathophysiology of Cardiac Performance
624
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
624
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:26Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
01:22Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
01:28Mechanism of Cardiac Arrhythmias
909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909